WallStSmart

Enovis Corp (ENOV)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2799% more annual revenue ($66.57B vs $2.30B). MRK leads profitability with a 4.8% profit margin vs -48.0%. ENOV appears more attractively valued with a PEG of 1.90. ENOV earns a higher WallStSmart Score of 55/100 (C).

ENOV

Buy

55

out of 100

Grade: C

Growth: 7.3Profit: 3.0Value: 6.3Quality: 5.0
Piotroski: 4/9Altman Z: -0.34

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENOVUndervalued (+34.6%)

Margin of Safety

+34.6%

Fair Value

$34.86

Current Price

$19.28

$15.58 discount

UndervaluedFair: $34.86Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENOV2 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

EPS GrowthGrowth
153.1%10/10

Earnings expanding 153.1% YoY

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

ENOV4 concerns · Avg: 3.5/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

Revenue GrowthGrowth
3.2%4/10

3.2% revenue growth

Market CapQuality
$1.07B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
4.2%3/10

Operating margin of 4.2%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ENOV

The strongest argument for ENOV centers on Price/Book, EPS Growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : ENOV

The primary concerns for ENOV are PEG Ratio, Revenue Growth, Market Cap.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

ENOV profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

ENOV carries more volatility with a beta of 1.43 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

ENOV scores higher overall (55/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enovis Corp

HEALTHCARE · MEDICAL DEVICES · USA

Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?